Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines
Michelle J. Clarke, Jann N. Sarkaria(Mayo Clinic), Evan A. Mulligan(Cancer Research UK), Brett L. Carlson(University of California, San Francisco), Paul A. Decker(University of California, San Francisco), Ann C. Mladek(Mayo Clinic), Patrick T. Grogan, Zhenkun Lou(Mayo Clinic), Mark A. Schroeder(MACOM (United States)), Nicola J. Curtin(Newcastle University), E. Ruth Plummer, Wenting Wu(Wenzhou Institute of Industrial Science)
Cited by 94
Related Papers
<i>TP53</i> and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
|New England Journal of Medicine|2016|783
Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts
|Neuro-Oncology|2008|387
Drivers, trends, and potential impacts of long-term coastal reclamation in China from 1985 to 2010
|Estuarine Coastal and Shelf Science|2016|333
Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177
|Journal of Clinical Oncology|2008|275
A c-Myc–SIRT1 feedback loop regulates cell growth and transformation
|The Journal of Cell Biology|2009|233